Published on in Vol 10, No 1 (2021): January

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/21727, first published .
Evaluation of Self-Care Activities and Quality of Life in Patients With Type 2 Diabetes Mellitus Treated With Metformin Using the 2D Matrix Code of Outer Drug Packages as Patient Identifier: Protocol for the DePRO Proof-of-Concept Observational Study

Evaluation of Self-Care Activities and Quality of Life in Patients With Type 2 Diabetes Mellitus Treated With Metformin Using the 2D Matrix Code of Outer Drug Packages as Patient Identifier: Protocol for the DePRO Proof-of-Concept Observational Study

Evaluation of Self-Care Activities and Quality of Life in Patients With Type 2 Diabetes Mellitus Treated With Metformin Using the 2D Matrix Code of Outer Drug Packages as Patient Identifier: Protocol for the DePRO Proof-of-Concept Observational Study

Christian Mueller 1, PhD;  Isabel Schauerte 2, PhD;  Stephan Martin 3, MD

1 Pharmaceuticals Medicine, Pharmaceuticals, Medical Excellence & Innovation Management, Data Generation, Bayer Vital GmbH, Leverkusen , DE

2 Institut Dr Schauerte , Munich , DE

3 Westdeutsches Diabetes- und Gesundheitszentrum , Düsseldorf , DE

Corresponding Author:

  • Christian Mueller, PhD
  • Pharmaceuticals Medicine, Pharmaceuticals
  • Medical Excellence & Innovation Management, Data Generation
  • Bayer Vital GmbH
  • Building K 56, 1D321
  • Leverkusen
  • DE
  • Phone: 49 214 30 46587
  • Email: christian.mueller4@bayer.com